Sign up USA
Proactive Investors - Run By Investors For Investors

Affimed teams up with Merck for cancer drug trial

The Phase 1b trial is expected to will be funded and conducted by Affimed, and it is expected to get underway in the first half of 2016.
Affimed teams up with Merck for cancer drug trial
Patient derived models showed up to 90% of a tumour could be eradicated.

Cancer drug developer Affimed N.V. (NASDAQ:AFMD) has struck a collaboration agreement with Merck which will involve a new drugs trial for patients with Hodgkin lymphoma.

Nasdaq quoted Affimed, which is headquartered in Germany, will fund and conduct the Phase 1b trial in which it will combine Merck's KEYTRUDA (pembrolizumab) drug, with Affimed's proprietary  candidate AFM13.

The trial will involve patients with Hodgkin lymphoma whose disease has relapsed or is refractory to chemotherapy. Its purpose will be to establish a dosing regimen, as well as assessing safety and efficacy.

It is expected that the study will begin in the first half of this year.

"AFM13, a first-in-class NK-cell engager, has shown an acceptable safety profile and preliminary antitumor activity in the first-in-human Phase 1 study,” said Dr Adi Hoess, Affimed chief executive.

“Additionally, preclinical studies indicate that a combination with an anti PD-1 therapy could act synergistically and represent an additional future treatment option for patients."

NK (or Natural Killer) cells are important in the activation of the innate immune system and the subsequent killing of tumor cells, Affimed explained in a statement.

The company also highlighted that in patient derived models at Stanford University AFM13, in combination with an anti-PD-1 antibody (Merck’s KEYTRUDA is an example of this kind of drug) demonstrated “impressive synergy” with up to 90% of the tumor eradicated.

Dr Eric Rubin, a vice president and therapeutic area head at Merck Research Laboratories,  meanwhile, said: "Evaluating the potential for innovative combination therapies through strategic collaborations in difficult-to-treat tumor types continues to be an important part of our clinical development program for KEYTRUDA.”

"In partnering with companies such as Affimed, we continue our efforts to bring forward new scientific breakthroughs for patients with Hodgkin lymphoma and the field of immuno-oncology overall."

Jamie_55a91591db06b.jpg


Register here to be notified of future INDU Company articles
View full INDU profile

US Market News Timeline

Related Articles

sareum-test-tubes.png
March 10 2016
November saw the Finland-based life sciences firm list on the London Exchange, raising €14.2mln.
Heart-cells.jpg
April 13 2016
Jim Phillips, Midatech’s chief executive, said Zuplenz offers relief from some of the most debilitating side-effects of common cancer treatments. Generically called ondansetron, the oral soluble film eases the problem of gritty residue, having to wear a patch and sedative side effects of dissolving tablets and injections.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC